Compatible with all Novo Nordisk FlexTouch insulin pens, Mallya smart sensor allows monitoring of injected doses to better compliance in the treatment of patients with diabetes
BIOCORP has signed a partnership agreement with Novo Nordisk to commercialise its Mallya smart sensor. (Credit: Novo Nordisk A/S )
French medical device maker BIOCORP has signed a partnership agreement with Danish healthcare company Novo Nordisk to commercialise its Mallya smart sensor, starting with Japan in the first half of 2023.
The new agreement is said to strengthen the relationship between Novo Nordisk and the French firm, which is centred on the development of Mallya. The firms signed global partnership within diabetes on digital health in September 2021.
The 2021 agreement included brands in the insulin market only, and earlier this year, an additional therapeutic area was added where the Danish company has a presence.
Mallya smart sensor for insulin injection pens is said to allow reliable monitoring of injected doses to provide better compliance in the treatment of diabetic patients. Referred as a non-medical device in Japan, the sensor attaches directly to Novo Nordisk FlexTouch insulin pens.
BIOCORP CEO Eric Dessertenne said: “We are very proud of this commercial launch in Japan through our partner Novo Nordisk. Japan is among the leading countries in the use of diabetes management devices and monitoring devices.
“This is a natural and high potential market for Mallya. In addition to that launch, we’re glad to have our relationship with Novo Nordisk being reinforced on an additional therapeutic area.”
BIOCORP said that Mallya attached to FlexTouch pens enables patients to automatically gather and record information about their daily insulin injections, such as the quantity of units, the date, and the time.
Through a mobile app, Mallya will allow patients to track their injection history as well as follow their treatment in real-time.
BIOCORP said that all Novo Nordisk FlexTouch insulin pens work with Mallya. The smart insulin pens can automatically record insulin dosing data and wirelessly transfer the data to mobile apps installed on the user’s smartphone.
Novo Nordisk pharma president and representative director Kasper Bødker Mejlvang said: “Earlier this year, we launched the first ever smart insulin pens in Japan (Novo 6 and NovoPen Echo Plus).
“However, most of our patients today in Japan use insulin with FlexTouch. As such, we are very pleased by working with BIOCORP, which manufactures and imports Mallya, to offer digital health to even more patients.”